Articles
published in the trade press:
- Business Wire 2008 (12/06/08) The CNS Market 2008 Report
- CNS Drug News (01/02/08) Senexis raises funds to further
develop AD compounds
- Business Weekly (31/01/08)
Senexis: unfolding the
science of senescence
- Business Weekly (23/01/08) Senexis lands £2.9m Wellcome
funding for Alzheimer's
- BioWorld International (22/01/08) Senexis awarded $5.7m from the
Wellcome Trust
- BioCentury (21/01/08) Senexis receives $5.7 million from the
Wellcome Trust
- Science Business (18/01/08) UK drug developer gets £3.7
million for Alzheimer's
- Dow Jones Venture Wire (18/01/08) Senexis swallows $7.3 million
series A
- Silicon Fen Business Report (18/01/08) Senexis raises
£2.9 million
- Chemical Business (17/01/08) Senexis secures £0.8 million
from BTG
- Current Patents Gazette (13/04/07) Senexis files small
molecule patent
- Business Week (16/01/07) Senexis and Daniolabs to
collaborate
- News RX (11/04/06) Alzheimer's compounds licensed to
Senexis
- Silicon Fen Business Report (04/02/06) BTG and the
Wellcome Trust invest in Senexis
- Biospace (12/2/2005)
Senexis and BioFocus collaborate to select development candidates
for Senexis' Alzheimer's disease targets
- Chemistry & Industry (17/01/05) Movers and Shakers
- BioCentury (18/04/2005)
Emerging Company Profile - Senexis: Break it up
- Genetic Engineering News (01/09/2004)
Biotechnology Firms Settle in Cambridge, UK
- In Vivo Europe (01/07/2004)
RX Starting Out: Senexis
- Current Opinion in Structural Biology (2003)
Design strategies for anti-amyloid agents
- Biotechnology Investment Today (Summer 2003)
Meptides: a potential treatment for neurodegenerative diseases
- Genetic Engineering News (01/02/2003)
New UK Company targets Amyloidosis
